Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: Pharmacology and efficacy

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2801-2806

  Noble, Charles O ^a   Krauze, Michal T ^b   Drummond, Daryl C ^c   Yamashita, Yoji ^b   Saito, Ryuta ^b   Berger, Mitchel S ^b   Kirpotin, Dmitri B ^c   Bankiewicz, Krystof S ^b   Park, John W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Hermes Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER MODEL; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; GLIOMA; INTRACRANIAL TUMOR; MALE; NANOPARTICLE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CONVECTION; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MALE; NANOSTRUCTURES; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645049055     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3535     Document Type: Article

References (38)

1. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-80.
2. Morrison PF, Chen MY, Chadwick RS, Lonser RR, Oldfield EH. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol Regul Integr Comp Physiol 1999;277:R1218-29.
3. Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 2002;1:131-9.
4. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development Mol Interv 2003;3:90-105.
5. Kunwar S. Convection-enhanced delivery of IL13-38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003;88:105-11.
6. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004;100:472-9.
7. Mardor Y, Roth Y, Lidar Z, et al. Monitoring response to convection-enhanced Taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001;61:4971-3.
8. Poepperl G, Goldbrunner R, Gildehaus FJ, Tanner P, Tatsch K. F-18 FET PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005;32:1018-25.
9. Gabizon A, Isacson R, Libson E, et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 1994; 33:779-86.
10. Zucchetti M, Boiardi A, Silvani A, Parisi I, Piccolrovazzi S, D'Incalci M. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol 1999;44:173-6.
11. Thigpen JT, Aghajanian CA, Alberts DS, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005;96:10-8.
12. Zamboni WC, Ramalingam S, Friedland DM, et al. Phase I and pharmacokinetic (PK) study of STEALTH® liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors. American Society of Clinical Oncology Annual Meeting; 2005; Orlando, FL. p. 2069.
13. Seiden MV, Muggia F, Astrow A, et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 2004;93:229-32.
14. Gelmon KA, Tolcher A, Diab AR, et al. Phase I study of liposomal vincristine. J Clin Oncol 1999;17:697-705.
15. Drummond DC, Noble CO, Mamot C, et al. Development of novel liposomal and receptor tyrosine kinase-targeted immunoliposomal vinorelbine formulations with improved drug retention [abstract]. Proc Am Assoc Cancer Res 2005;56:4394.
16. Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. In press 2006.
17. Drummond DC, Marx C, Guo Z, et al. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res 2005;11:3392-401.
18. Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003;9:2940-9.
19. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17:1516-25.
20. Chou R, Chen A, Lau D. Complete response of brain metastases to irinotecan-based chemotherapy. J Clin Neurosci 2005;12:242-5.
21. Mathijssen RHJ, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
22. Lokiec F, duSorbier BM, Sanderink GJ. Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 1996;2:1943-9.
23. Mamot C, Nguyen JB, Pourdehnad M, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol 2004;68:1-9.
24. Saito R, Bringas JR, McKnight TR, et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 2004;64:2572-9.
25. Saito R, Krauze MT, Bringas J, et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol 2005;196:381-9.
26. Krauze MT, McKnight TR, Yamashita Y, et al. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Prot 2005;16:20-6.
27. Krauze MT, Saito R, Noble C, et al. Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol 2005;196: 104-11.
28. Bartlett GR. Phosphorous assay in column chromatography. J Biol Chem 1959;234:466-8.
29. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000;164:2-14.
30. Cao SS, Rustum YM. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 2000;60:3717-21.
31. Escoriaza J, Aldaz A, Castellanos C, Calvo E, Giraldez J. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid chromatography: application to clinical pharmacokinetic studies. J Chromatogr B 2000;740:159-68.
32. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B 1997;691:161-71.
33. Zufia L, Aldaz A, Giraldez J. Separation methods for camptothecin and related compounds. J Chromatogr B 2001;764:141-59.
34. Friedman HS, Keir ST, Houghton PJ. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in grain tumors. Cancer 2003;97:2359-62.
35. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-7.
36. Chen TC, Su S, Fry D, Liebes L. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 2003;97:2363-73.
37. Nakatsu S, Kondo S, Kondo Y, et al. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 1997:39:417-23.
38. Reardon DA, Friedman HS, Powell JBJ, Gilbert M, Yung WK. Irinotecan: promising activity in the treatment of malignant glioma. Oncology 2003;17:9-14.